Companies › Lallemand Pharma
1 active drug program in 1 registered trial: 1 Phase 4; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Bacterial Lysates (PMBL®, ISMIGEN®) Polyvalent mechanical bacterial lysate - stimulates innate and adaptive immune responses t | – | Phase 4 | Respiratory Tract Infections (RTI) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07578012 | Bacterial Lysates (PMBL®, ISMIGEN®) | Phase 4 | Respiratory Tract Infections (RTI) | Infectious disease | Mar 2027 |
No annotated target.
–
Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) MicuRx Jiangxi Qingfeng Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.